Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Grgur Mirić

Showing results (1-10 of 5) with videos related to

Pageof 1
Sort By:
Brachytherapy|January 6, 2026
Randomized trial of dose de-escalation in low-risk prostate cancer patients implanted with Pd-103Martin King, Grgur Mirić, Mutlay Sayan, et al.
Prostate Cancer and Prostatic Diseases|September 11, 2025
Brachytherapy monotherapy for favorable and select unfavorable intermediate risk prostate cancerMartin King, Grgur Mirić, Robert Galbreath, et al.
Advances in Radiation Oncology|July 13, 2026
Nonprostate Cancer Deaths Best Predict Long-Term Survival in Men Aged ≤59 Years Treated With Low Dose Rate Brachytherapy With or Without Supplemental Therapies: A Mandate for Health EnhancementPeter Orio, Grgur Mirić, Robert Galbreath, et al.
BMC Geriatrics|December 16, 2025
Long-term prostate cancer survival outcomes including patterns of death in men >=75 years of age treated with low dose rate brachytherapyShalini Moningi, Grgur Mirić, Robert Galbreath, et al.
Brachytherapy|December 5, 2025
National patterns of brachytherapy boost use for intermediate- and high-risk prostate cancer: Bridging the gap between evidence and practiceAlicia C Smart, Yetkin Tuac, Zhiyu Qian, et al.
Pageof 1

Showing results (1-10 of 5) with videos related to

Sort By:
Pageof 1
Brachytherapy|January 6, 2026
Randomized trial of dose de-escalation in low-risk prostate cancer patients implanted with Pd-103Martin King, Grgur Mirić, Mutlay Sayan, et al.
Prostate Cancer and Prostatic Diseases|September 11, 2025
Brachytherapy monotherapy for favorable and select unfavorable intermediate risk prostate cancerMartin King, Grgur Mirić, Robert Galbreath, et al.
Advances in Radiation Oncology|July 13, 2026
Nonprostate Cancer Deaths Best Predict Long-Term Survival in Men Aged ≤59 Years Treated With Low Dose Rate Brachytherapy With or Without Supplemental Therapies: A Mandate for Health EnhancementPeter Orio, Grgur Mirić, Robert Galbreath, et al.
BMC Geriatrics|December 16, 2025
Long-term prostate cancer survival outcomes including patterns of death in men >=75 years of age treated with low dose rate brachytherapyShalini Moningi, Grgur Mirić, Robert Galbreath, et al.
Brachytherapy|December 5, 2025
National patterns of brachytherapy boost use for intermediate- and high-risk prostate cancer: Bridging the gap between evidence and practiceAlicia C Smart, Yetkin Tuac, Zhiyu Qian, et al.
Pageof 1